March 5th 2018
March 2nd 2018
David R. Spigel, MD, discusses the status of immunotherapy in locally advanced NSCLC and highlights recent milestones.
Alterations in DNA damage response and repair genes were associated with an increased response to anti-PD-1/PD-L1 antibodies in patients with metastatic urothelial carcinoma.
March 1st 2018
Claude Denham, MD, discusses the challenges with immunotherapy in NSCLC cancer, as well as the promise of combination therapy.
February 27th 2018